H1N1 influenza:
Responding to a pandemic
As H1N1 flu continues to make headlines across the world, GlaxoSmithKline is responding to the flu pandemic.
GSK is investing in the development of vaccines for the influenza A (H1N1) strain of flu and the increased production of the anti-viral Relenza through its own manufacturing facilities and through partnerships with other companies.
Announcements
![]()
Recent headlines
[an error occurred while processing this directive]
[an error occurred while processing this directive]
February 04, 2010
GSK launches new specialist unit to research and develop medicines for rare diseases
February 04, 2010
GSK announces appointment of Philippe Fauchet as President of GSK Japan
February 04, 2010
Results announcement for the fourth quarter 2009
GSK News Services
Leading the way to make clinical trial data more transparent
Learn about flu treatment
Find health information
Save money on your prescriptions
Join GSK
Updated February 4, 2010
© 2001 - 2010 GlaxoSmithKline - All rights reserved


